Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2775-2782

  Dickinson, Laura ^a,b   Boffito, Marta ^c   Back, David ^b   Else, Laura ^b   Von Hentig, Nils ^d   Davies, Geraint ^b   Khoo, Saye ^b   Pozniak, Anton ^c   Moyle, Graeme ^c   Aarons, Leon ^e  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Chelsea and Westminster Foundation Trust   (United Kingdom)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ETHNICITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NONLINEAR SYSTEM; PREDICTION; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BODY MASS INDEX; FEMALE; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRIMIDINONES; RITONAVIR;

EID: 79956328920     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00887-10     Document Type: Article

References (16)

1. Abbott Laboratories. 15 June 2010, accession date. Kaletra (lopinavir/ritonavir) tablets and oral solution. US prescribing information. Abbott Laboratories, North Chicago, IL. http://www.rxabbott.com/pdf/ kaletratabpi.pdf.
2. Abbott Laboratories. 15 June 2010, accession date. Kaletra 200 mg/50 mg film-coated tablets. Summary of product characteristics. Abbott Laboratories, North Chicago, IL. http://www.medicines.org.uk/emc/medicine/18442.
3. Baldwin, J. R., et al. 1999. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, abstr. 657.
4. Beal, S., and L. B. Sheiner. 1989-1998. NONMEM users guide. ICON Development Solutions, Ellicott City, MD.
5. Boffito, M., et al. 2008. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir. Ther. 13:901-907.
6. Boffito, M., et al. 2004. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 18:1291-1297. (Pubitemid 38822707)
7. Else, L., et al. 2010. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878:1455-1465.
8. Fahmi, O. A., et al. 2008. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab. Dispos. 36:1698-1708.
9. Hill, A., J. van der Lugt, W. Sawyer, and M. Boffito. 2009. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 23:2237-2245.
10. Klein, C. E., et al. 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immune Defic. Syndr. 44:401-410.
11. Kumar, G. N., et al. 2004. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res. 21:1622-1630.
12. Molto, J., et al. 2008. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin. Pharmacokinet. 47:681-692.
13. Oldfield, V., and G. L. Plosker. 2006. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 66:1275-1299.
14. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
15. Stephan, C., et al. 2004. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503-508. (Pubitemid 38365878)
16. Tomaka, F., et al. 2009. Effects of ritonavir-boosted darunavir vs. ritonavirboosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med. 10:318-327.